source
- Pharma access plans rise to 69% of late-stage drugs but gaps remain for non-communicable diseasesA new analysis shows that many large drug makers are expanding programs to make medicines available in low- and middle‑income markets, but progress is uneven across disease areas. Access plans now…
- Democratic committee chairs send letters to 27 drugmakers demanding details on Trump-era MFN pricing agreementsIncoming Democratic chairs of the Senate Finance Committee and the House Energy and Commerce, Ways and Means, and Education and Labor committees have issued a new round of letters to all 27 drugmak…